OxyHealth

Overview

OxyHealth is the dominant US consumer hyperbaric oxygen chamber manufacturer by volume — over 18,000 chambers sold, used in roughly 65% of US hyperbaric clinics, and adopted by US Special Forces, the International Olympic Committee, and a wide range of professional sports teams. Its FDA 510(k) clearance (K041007) and 28-year manufacturing history give it the strongest institutional credibility of any consumer HBOT brand.

The trade-off is structural and important: all OxyHealth soft-shell models are capped at 1.3 ATA. Most published HBOT clinical evidence — for wound healing, traumatic brain injury, post-stroke recovery — uses 2.0–2.5 ATA in hospital-grade hard-shell chambers. The 1.3 ATA “mild HBOT” range has a smaller published evidence base, primarily in neurodegenerative-disease and recovery contexts.

The buyer’s question isn’t whether OxyHealth makes a good chamber. It does. The question is whether 1.3 ATA matches the use case you have in mind.

What We Measured

Note: This review is based on the FDA 510(k) clearance file (K041007), OxyHealth’s published product specifications, and clinical-deployment data. Hands-on chamber pressure testing, oxygen concentration verification at the mask, and noise-level measurement are pending.

Pressure capability and ATA range

All OxyHealth soft-shell chambers cap at 1.3 ATA — by physical design and FDA-clearance constraint. This is consistent across the Vitaeris 320, Solace 210, Quamvis 320, and Fortius 420 product line. Higher-pressure operation requires hard-shell chambers (which OxyHealth does not currently make for the consumer market) or imported alternatives (OxyHelp, OxyRevo).

Oxygen delivery

Soft-shell chambers operate by pressurizing ambient air; clinical-grade therapy requires an oxygen concentrator delivering 90%+ purity O₂ to the user via mask or hood. OxyHealth’s published protocols assume concentrator pairing — but the concentrator is typically sold separately. A “$23K chamber” is functionally a $25K–$26K system once you add a clinical-grade concentrator and ancillaries.

FDA 510(k) clearance verification

OxyHealth holds 510(k) clearance K041007. This is verifiable on accessdata.fda.gov by searching the K-number; the clearance covers OxyHealth’s portable hyperbaric chambers as Class II medical devices. Importantly: 510(k) clearance is a “substantial equivalence” pathway, not an efficacy pathway — it certifies the device is similar in safety and effectiveness to a predicate device, not that any specific therapeutic claim is approved.

Published clinical evidence

The published HBOT evidence base divides cleanly: 1.5–2.5 ATA hard-shell HBOT has decades of clinical literature for wound healing, decompression sickness, carbon monoxide poisoning, and several FDA-approved indications. 1.3 ATA “mild HBOT” has a smaller, more recent evidence base — mostly for traumatic brain injury, post-concussion syndrome, and recovery contexts. Both are legitimate; the buyer should know which evidence base they’re invoking.

3-Year Cost of Ownership

Component	Cost
OxyHealth Vitaeris 320	~$23,000
Medical-grade O₂ concentrator (separate)	~$2,500
Replacement masks/hoods over 3 yrs	~$300
Electricity (estimate, 200–400W × 1hr/day × 3 yrs)	~$200
3-year total — Vitaeris 320 system	~$26,000

Compare: Summit-to-Sea Grand Dive ($7,000 + concentrator ~$2,500 = ~$10,000), Macy-Pan ST-Series ($5,500 + concentrator = ~$8,500), OxyRevo / OxyHelp hard-shell at 1.5+ ATA ($15,000–$50,000+ depending on model — but check FDA clearance status).

OxyHealth sits at premium pricing for soft-shell HBOT. The cost premium reflects the FDA clearance, manufacturing track record, and warranty support — not pressure capability.

Regulatory Status

FDA 510(k) Cleared (K041007). OxyHealth chambers are Class II medical devices with a substantial-equivalence clearance to a predicate hyperbaric chamber. Verifiable directly on accessdata.fda.gov.

This is the strongest regulatory position in consumer soft-shell HBOT. Many imported chambers (Macy-Pan, OxyHelp, OxyRevo) lack FDA clearance entirely and may be sold under “registered” status (administrative listing, not clearance) or no FDA filing at all. For HSA/FSA reimbursement eligibility — which can apply to medically-prescribed HBOT — FDA clearance status matters.

When OxyHealth Makes Sense — And When It Doesn’t

Strong fit:

• You’re a clinic, professional athlete, or institutional buyer needing established warranty support and the largest US service network.
• You want FDA-cleared status for HSA/FSA reimbursement, regulatory comfort, or insurance documentation.
• 1.3 ATA mild-HBOT matches your use case (recovery, wellness, post-concussion) and you’ve reviewed the evidence base.

Weaker fit:

• You need 1.5–2.5 ATA for an indication that the published clinical literature studies at that pressure (most wound-healing, decompression, carbon monoxide).
• You’re cost-sensitive — Summit-to-Sea or Macy-Pan deliver similar 1.3 ATA mild HBOT at half the price. The brand premium is real but optional.
• You expect online transparent pricing — OxyHealth often requires dealer contact.

Verdict: Conditional

OxyHealth earns a conditional verdict on the strength of its FDA 510(k) clearance, manufacturing track record, and institutional credibility — balanced against the price premium vs functionally similar competitors and the structural pressure ceiling at 1.3 ATA. For institutional and professional buyers, OxyHealth is the conservative right answer. For cost-sensitive consumer buyers willing to verify a competitor’s FDA status independently, alternatives exist.

If your use case requires 1.5+ ATA hard-shell HBOT, OxyHealth is not the right product family — look at imported hard-shell brands and verify their FDA status individually.

Changelog

• 2026-05-05: Initial review published based on FDA 510(k) clearance file (K041007) and OxyHealth product specifications. Hands-on pressure testing pending.